Hematological toxicity of radioimmunotherpy with 90Y Ibritumomab

Radioimmunotherapy with 90Y Ibritumomabu (Zevalin, BSP) is a new method of systemic radiotherapy applicable to B-cell lymphoma patients. It may be delivered as a short outpatient procedure, with few adverse effects other than hematological toxicity. In the paper, we present length and depth of cytop...

Full description

Saved in:
Bibliographic Details
Published inPrzeglad lekarski Vol. 69; no. 3; p. 107
Main Authors Jurczak, Wojciech, Szostek, Marta, Jakóbczyk, Małgorzata, Staszczak, Anna Sowa, Zimowska-Curyło, Dagmara, Giza, Agnieszka, Sobociński, Marcin, Hubalewska-Dydejczyk, Alicja, Skotnicki, Aleksander B
Format Journal Article
LanguagePolish
Published Poland 2012
Subjects
Antibodies, Monoclonal - adverse effects
Hematologic Diseases - etiology
Humans
Lymphoma, B-Cell - radiotherapy
Radioimmunotherapy - adverse effects
Yttrium Radioisotopes - adverse effects
Online AccessGet more information

Cover

More Information
Summary:Radioimmunotherapy with 90Y Ibritumomabu (Zevalin, BSP) is a new method of systemic radiotherapy applicable to B-cell lymphoma patients. It may be delivered as a short outpatient procedure, with few adverse effects other than hematological toxicity. In the paper, we present length and depth of cytopenias, together with the results of additional tests performed to reveal the possible pathomechanisms, based on 102 patients treated at the University Hospital in Krakow.
ISSN:0033-2240